

1 **Stability Monitoring of Phytogetic Constituents and Physicochemical**
2 **Properties of Pulmofarm[®] T Herbal Respiratory Premix during Feed**
3 **Pelletization Stress**
4
5

6 **ABSTRACT**

7 Feed represents a major input in poultry, cattle, and swine production, accounting for
8 approximately 50–70% of total production costs. Feed processing technologies such as
9 pelletization can enhance feed efficiency, reduce wastage, and improve digestibility and
10 palatability. However, the elevated temperature and moisture involved in pelletization may
11 influence the stability of phytogetic feed additives. Livestock species are highly susceptible to
12 respiratory disorders caused by multiple predisposing factors including chronic stress, bacterial
13 or fungal infections, secondary coliform organisms, and environmental allergens. Pulmofarm[®] T
14 Premix, a phytogetic herbal formulation, is widely used to alleviate symptoms associated with
15 chronic respiratory disease (CRD) such as sniffing, rattling, sneezing, coughing, and respiratory
16 distress. The present study evaluated the phytogetic and physicochemical stability of
17 Pulmofarm[®] T Premix under simulated pelletization stress conditions.

18 The formulation was exposed to controlled thermal (90 °C) and moisture (2.0% w/w) conditions
19 for 0, 5, and 10 minutes. Stability was assessed using reverse-phase high-performance liquid
20 chromatography with photodiode array detection (RP-HPLC-PDA) and high-performance thin-
21 layer chromatography (HPTLC), along with physicochemical evaluations.

22 The results demonstrated no significant degradation of key phytogetic markers under
23 pelletization conditions. The concentrations of glycyrrhizin (2542.91 ppm \pm 3.77%, RT 16.60
24 min) and thymol (280.21 ppm \pm 4.45%, RT 18.30 min) remained stable, with no notable changes
25 in chromatographic peak areas or retention factor values compared to control samples. The
26 analytical methods employed were rapid, sensitive, and reliable for stability assessment.

27 These findings confirm that Pulmofarm[®] T Premix remains stable during feed pelletization,
28 supporting its suitability for incorporation into pelleted feed systems. Furthermore, the study
29 contributes to the development of robust stability monitoring parameters for herbal feed
30 additives, addressing a critical challenge in the nutraceutical and phytogetic feed additive
31 industry.

32

33 **Keywords:**Pulmofarm[®] T Premix, Thymol, Glycyrrhizin, Pelletization, Chromatography

34

UNDER PEER REVIEW IN IJAR

35 1.0 INTRODUCTION

36 Respiratory diseases remain a major health challenge in livestock production systems,
37 particularly in poultry, cattle, and swine, where environmental, infectious, and management-
38 related factors predispose animals to respiratory distress and reduced productivity. In veterinary
39 industry, medicated feeds containing sub-therapeutic levels of pharmacologically active
40 phytogetic substances are frequently utilized for disease prevention and improvement of
41 production performance [1]. Consequently, herbal feed additives have gained increasing
42 attention as natural alternatives for supporting respiratory health and improving livestock
43 resilience [2-3].

44 Pulmofarm[®] T Premix, a polyherbal respiratory tonic developed by Zenex Animal Health India
45 Private Limited, is used in poultry, cattle, swine, and other livestock species for the prevention
46 and supportive management of respiratory disorders. Since, they are highly susceptible to
47 respiratory infections caused by pathogens such as *Mycoplasma gallisepticum*, *Pasteurella*
48 *multocida*, and *Bordetella bronchiseptica*, along with secondary infections by coliform
49 organisms and environmental allergens. In addition to microbial pathogens, several stress-related
50 factors—including transportation, poor ventilation, temperature and humidity fluctuations, high
51 stocking density, and the introduction of new animals into established flocks—contribute
52 significantly to the onset and progression of respiratory disease [4].

53 Pulmofarm[®] T Premix has been reported to alleviate clinical manifestations associated with
54 chronic respiratory disease (CRD), including sniffing, sneezing, coughing, rattling, and other
55 signs of respiratory distress [5]. The formulation contains herbs such as *Glycyrrhiza glabra* and
56 *Adhatodavasica*, which are widely recognized for their immunomodulatory, expectorant,
57 antimicrobial, demulcent, analgesic, and antispasmodic properties [6-7]. The therapeutic activity
58 of the formulation is largely attributed to bioactive phytoconstituents, including glycyrrhizin
59 from *Glycyrrhiza glabra* and essential oils such as thymol present in *Trachyspermum mammi*, as
60 well as other phytochemicals present in *Adhatodavasica* leaves [8]. These compounds exhibit
61 bronchodilatory and mucolytic properties, reducing bronchospasm, and alleviating cough
62 associated with acute and chronic bronchitis. Additionally, *Glycyrrhiza glabra* demonstrates
63 demulcent and anti-inflammatory activity that helps relieve irritation of bronchial mucosa, sore
64 throat, and asthma-like conditions, making it a widely used herbal remedy for respiratory
65 ailments [9].

66 Incorporation of herbal premixes such as Pulmofarm[®] T into feed formulations provides
67 opportunities to enhance livestock productivity and production efficiency. Consequently,
68 optimizing feed processing methods has become an important area of research in animal
69 nutrition. Among these methods, feed pelleting is the most widely used heat-treatment process in
70 poultry and animal feed manufacturing. Pelleting involves the agglomeration of finely ground
71 feed particles into larger pellets, improving feed handling characteristics, increasing feed intake,
72 and enhancing growth performance [10-11].

73 During pellet production, mash feed is transferred from storage bins to a feeder and conditioner,
74 where it is subjected to heat and moisture before entering the pelleting chamber. The conditioned
75 mash is then forced through a metal die to form pellets, which are subsequently cooled to
76 stabilize their structure [12]. Feed manufacturers frequently adjust processing variables; such as
77 conditioning temperature, moisture content, and residence time—to improve pellet durability and
78 physical quality [13]. Although these modifications enhance pellet quality, the exposure of feed
79 additives to elevated temperature and moisture during pelletization may adversely affect their
80 stability and biological efficacy.

81 Despite the growing use of herbal feed additives in livestock nutrition, limited studies have
82 investigated the stability of herbal formulations during feed processing. The stability of herbal
83 feed additives can be influenced by multiple factors, including temperature, moisture,
84 environmental conditions, particle size, and variability in secondary metabolite concentrations
85 [14]. Therefore, monitoring the stability of bioactive constituents during feed processing is
86 essential to ensure product quality and therapeutic efficacy.


87 The present study was designed to evaluate the stability profile of Pulmofarm[®] T Premix under
88 pelletization stress conditions, where the formulation is exposed to elevated temperature and
89 moisture for short durations during feed processing. In particular, variations in the concentration
90 of key secondary metabolites were investigated as potential stability markers. Glycyrrhizin and
91 thymol were selected as representative bioactive compounds due to their established
92 pharmacological relevance and their contribution to the respiratory therapeutic activity of the
93 formulation.

94 Quantitative assessment of these marker compounds, along with evaluation of physicochemical
95 properties, was performed using reverse-phase high-performance liquid chromatography with
96 photodiode array detection (RP-HPLC-PDA) and high-performance thin-layer chromatography

97 (HPTLC). These analytical techniques provide rapid, sensitive, and reliable methods for
98 monitoring phytochemical stability in complex herbal formulations.

99 The objective of this work was therefore to conduct a comprehensive pelletization stress study to
100 evaluate changes in physicochemical characteristics and the stability of glycyrrhizin and thymol
101 [Figure 1] in Pulmofarm[®] T Premix using a sequential analytical approach involving RP-HPLC-
102 PDA and HPTLC techniques. The findings of this investigation are expected to contribute to the
103 development of robust stability monitoring parameters for herbal feed additives, addressing a
104 critical challenge in the animal health and feed industry.

105



106

107

Figure 1: Structure of Glycyrrhizin and Thymol

108

109

110 2.0 MATERIAL AND METHODS

111 Chemicals and reagents:

112 All the reagents and solvents were of AR or HPLC grade as per requirement. The active
113 reference compound glycyrrhizin and thymol were procured from the Sigma Aldrich, while latest
114 controlled sample of Pulmofarm[®] T Premix was obtained from the QA/QC department of Zenex
115 Animal Health India Private Limited, Baddi.

116

117

118 **Instrumentation:**

119 The RP-HPLC system consisted of WATERS, binary pump 515 with PDA 2996 detector, USA.
120 Separation was obtained on Phenomenex Luna C18 column (250 mm × 4.6 mm, 5 µm). The data
121 were acquired on the Empower 2.0 controlling software (all equipment from Waters, Milford).
122 The HPTLC system consisted of CAMAG-HPTLC system with Scanner III, Linomat V, twin
123 trough chambers and Vision-Cats software.

124
125 **Pelletization stress stability testing:**

126 The formulated Pulmofarm[®] T Premix was assessed for stability under pelletization stress
127 conditions: controlled 90°C temperature and moisture (2.0 % w/w) exposure for zero, five, and
128 ten minute interval of times. Physicochemical properties, RP-HPLC-PDA, and HPTLC
129 studies were used to monitor stability.

130
131 **Physicochemical parameters:**

132 The physical parameters like description, total ash content, extractive values, calcium content,
133 active marker compounds were evaluated for the three samples under study i.e. (1) control, (2)
134 sample exposed to 90°C, 2.0 % w/w moisture for 05 minutes and (3) sample exposed to 90°C,
135 2.0 % w/w moisture for 10 minutes.

136
137 **High performance liquid chromatography (RP-HPLC-PDA) study:**

138 ***Preparation of test solution:***

139 Around 5g of each Pulmofarm[®] T Premix sample was weighed accurately and transferred into a
140 250mL round bottom flask. 70mL of methanol was added, and the mixture was refluxed on a
141 water bath using a reflux condenser for one hour. This process was repeated two more times. The
142 solution was then filtered and concentrated to 100mL using a rotavapor, transferred into a
143 100mL volumetric flask, and made up to volume with methanol. Finally, the solution was
144 filtered through a 0.45 µm filter before being injected into the HPLC system.

145 ***Preparation of standard Thymol solutions:***

146 Around 2.5 mg of thymol reference standard was weighed accurately and transferred to a 25 mL
147 volumetric flask. 20 mL of methanol was added, the mixture was sonicated for 5 minutes, and

148 the volume was made up with the same solvent. The solution was filtered through a 0.45 µm
149 filter before being injected into the HPLC system.

150 ***Preparation of standard Glycyrrhizin solutions:***

151 Around 5 mg of glycyrrhizin reference standard was weighed accurately and transferred to a 25
152 mL volumetric flask. 20 mL of methanol was added, the mixture was sonicated for 5 minutes,
153 and the volume was made up with the same solvent. The solution was filtered through a 0.45 µm
154 filter before being injected into the HPLC system.

155 ***Chromatographic conditions for Thymol analysis:***

156 Initial trials were carried by a gradient mode of analysis using the mobile phase, which consisted
157 of a gradient solvent system of water (containing 0.2% acetic acid) and acetonitrile (from 50:50
158 to 100:0 over 20 min). Experiments concluded lack of resolution of a complex mixture of
159 different phytoconstituents and time consuming using the gradient approach of analysis. The
160 simple isocratic mode was opted comprising water and acetonitrile in 50:50 ratio. The elution
161 was clear and well-separated peaks of thymol with a flow rate of 1 mL/min over a runtime of 30
162 min. The eluent was monitored at 280 nm. The mobile phase was filtered through 0.45 µm
163 Millipore membrane filter and degassed before use. The injection volume was 20 µL and all
164 analysis were performed at ambient temperature.

165 ***Chromatographic conditions for Glycyrrhizin analysis:***

166 The simple isocratic mode was opted comprising potassium dihydrogen phosphate buffer
167 solution of 5.3mM and acetonitrile in 65:35 ratio having a pH of 3.5 with acetic acid. The elution
168 was clear and well-separated peaks of glycyrrhizin with a flow rate of 1 mL/min over a runtime
169 of 25 min. The eluent was monitored at 254 nm. The mobile phase was filtered through 0.45 µm
170 Millipore membrane filter and degassed before use. The injection volume was 20 µL and all
171 analysis were performed at ambient temperature.

172

173 **High performance thin layer chromatography (HPTLC) study:**

174 ***Preparation of test solution:***

175 (a) Weighed accurately around 5g of each Pulmofarm[®] T Premix samples and transferred to a
176 250mL round bottom flask. Added 200 mL of chloroform and refluxed on water bath for 2 hours,
177 cooled, filtered and concentrated up to 100 mL using rotavapor, transferred in to a 100

178 mL volumetric flask and made up the volume to 100 mL with chloroform. Filter the solution
179 using 0.45µm syringe filter. Clear resulting solution thus obtained was used for HPTLC analysis.

180 (b) Dried the marc from above process on water bath and transferred to a 250 mL round bottom
181 flask, added 200 mL methanol, refluxed on water bath for 2 hours, cooled and filtered through
182 filter paper, concentrated up to 100 mL using rotavapor, transferred in to a 100 mL volumetric
183 flask and made up the volume to 100 mL with methanol. Filter the solution using 0.45µm
184 syringe filter. Clear resulting solution thus obtained was used for HPTLC analysis.

185

186 ***Application for chloroform fraction:***

187 Applied 10 µl of solution of each control and exposed sample extracts (control, sample exposed
188 to 90°C, 2.0 % w/w moisture for 05 minutes and sample exposed to 90°C, 2.0 % w/w moisture
189 for 10 minutes) on TLC plate precoated with Silica gel 60F 254 using Linomat applicator. TLC
190 plate was then dipped in saturated twin trough chamber containing the mobile phase of Toluene:
191 Ethyl acetate 70:30. Eluted TLC plate then scanned in CAMAG-HPTLC Scanner III under
192 Tungsten lamp at 480 nm in absorbance mode. Peaks were integrated and areas were determined.
193 Spectral scan was taken of all peaks to confirm that spot in control and exposed samples track
194 are similar.

195

196 ***Application for Methanol soluble fraction:***

197 Applied 10 µl of solution of each control and exposed sample extracts (control, sample exposed
198 to 90°C, 2.0 % w/w moisture for 05 minutes and sample exposed to 90°C, 2.0 % w/w moisture
199 for 10 minutes) on TLC plate precoated with Silica gel 60F 254 using Linomat applicator. TLC
200 plate then dipped in saturated twin trough chamber containing the mobile phase of Chloroform:
201 Methanol in 95:05 ratio. Eluted TLC plate then scanned in CAMAG-HPTLC scanner III under
202 Deuterium lamp at 254 nm in absorbance mode. Peaks were integrated and areas were
203 determined. Spectral scan was taken of all peaks to confirm that spot in control and exposed
204 samples track are similar.

205

206

207 **3.0 RESULTS AND DISCUSSION**

208 The impact of heat exposure on the glycyrrhizin and thymol content, physicochemical
209 characteristics, and chromatographic fingerprint profile of Pulmofarm[®] T Premix was
210 systematically evaluated. The formulation was divided into three groups: a control sample and
211 samples subjected to heat treatment at 90°C in the presence of 2.0% w/w moisture for 0, 5, and
212 10 minutes.

213 Assessment of key physicochemical parameters—including extractive values, ash content, and
214 calcium content—revealed no significant variation among the treated samples compared with the
215 control [Table 1], indicating that short-term exposure to the applied thermal and moisture
216 conditions did not materially affect the basic physicochemical properties of the formulation.

217 Quantitative analysis of the marker compounds glycyrrhizin and thymol in the treated samples
218 was performed using chromatographic techniques to evaluate the formulation's stability under
219 pelletization-like stress conditions. Analytes quantification were performed via RP-HPLC-PDA
220 utilizing validated methodologies developed in alignment with ICH Q2(R1) statistical guidelines
221 (WHO, 1997) [15-16]. While the protocol for thymol underwent a new in-house development
222 and validation [Tables 2, Table 3, Table 4], the analysis of glycyrrhizin followed previously
223 established and peer-reviewed procedures (Ravikanth K. et al., 2015) [17]. The chromatograms
224 demonstrated well-resolved peaks for glycyrrhizin and thymol with retention times of 18.30
225 minutes and 16.60 minutes, respectively. Spectral scans and minimal differences in peak areas
226 ($\leq 5.0\%$) across all treated samples provided clear evidence that no significant degradation
227 occurred under the applied heat and moisture treatments [Table 5 & 6, Figure 4 & 5].

228 Further characterization was performed using High-Performance Thin Layer Chromatography
229 (HPTLC) to assess potential qualitative changes in the formulation profile. Chloroform extracts
230 analyzed at 480 nm and methanolic extracts analyzed at 254 nm provided complementary
231 fingerprint information. The HPTLC fingerprint profiles and overlay peak scans of both solvent
232 extracts from all three treatment conditions [Table 7, Table 8; Figure 2, Figure 3] showed
233 consistent band patterns without the appearance of additional degradation products.

234 Moreover, variations in the total chromatographic area and active marker compounds in heat-
235 exposed samples relative to the control were within $\pm 10\%$, which falls within acceptable
236 analytical variability limits. Collectively, these findings indicate that Pulmofarm[®] T Premix
237 maintains chemical integrity and marker compound stability under the evaluated thermal and
238 moisture conditions, supporting its stability during pelletization-related processing.

239
240
241
242

Table 1: Physicochemical parameters of Pulmofarm[®] T Premix.

S. No.	Parameters	Pulmofarm [®] T PremixControl (00 minutes at 90 ⁰ C and 2.0% moisture)	Pulmofarm [®] T Premix: After exposure (05 minutes at 90 ⁰ C and 2.0% moisture)	Pulmofarm [®] T Premix: After exposure (10 minutes at 90 ⁰ C and 2.0% moisture)
1	Description	Greenish yellow color fine powder with herbaceous odour	Greenish yellow color fine powder with herbaceous odour	Greenish yellow color fine powder with herbaceous odour
2	Water soluble extractive value	21.64 % w/w	21.34 % w/w	19.41 % w/w
3	Crude ash	17.95 % w/w	17.47 % w/w	17.37 % w/w
4	Calcium content	6.48 % w/w	6.46 % w/w	6.43 % w/w

243
244

Table 2: Parameters.

S. no.	Parameters	Data	RSD
1	Peak area	1196219	0.95
2	Retention time (min)	18.30	0.93
3	Theoretical plates	9954	0.98
4	Tailing factor	0.981	1.04

245
246
247

Table 3: Results of precision, LOD, LOQ, linear regression analysis, and their correlation coefficient for quantitative analysis of thymol by RP-HPLC-PDA.

S. no.	Parameters	Thymol
1	Concentration range for linearity [$\mu\text{g ml}^{-1}$]	18.0 to 72.0
2	Correlation Coefficient (r ²)	0.999
3	Amount of marker compound in Pulmofarm [®] T Premix [%] (w/w) ^a	0.027
4	Intermediate precision (Reproducibility) RSD [%]	0.50
5	Intraday 1	0.43
6	Interday 3	0.35

7	LOD	0.062 $\mu\text{g ml}^{-1}$
8	LOQ	0.186 $\mu\text{g ml}^{-1}$

248 **Table 4: Results from determination of recovery.**

S. no.	Parameters	Thymol		
		1	Initial concentration in formulation [mg g ⁻¹]	0.27
2	Concentration added [mg g ⁻¹]	0.0	2.0	4.0
3	Total concentration [mg g ⁻¹]	0.27	2.27	4.27
4	Concentration found [mg g ⁻¹]	0.264	2.07	3.92
5	RSD [%] (n=7)	0.95	0.93	0.92
6	Recovery [%]	97.78	91.19	91.80
7	Mean recovery [%]	93.59		

249

250

251 **Table 5: Thymol contents by RP-HPLC-PDA in Pulmofarm[®] T Premix.**

Sample details	Thymol content (ppm)	% Difference in Thymol content with respect to control sample
Pulmofarm [®] T Premix - control	281.21	0.00
Pulmofarm [®] T Premix after exposure to heat for 05 minutes at 90°C	272.54	-3.18
Pulmofarm [®] T Premix after exposure to heat for 10 minutes at 90°C	269.22	-4.45

252

253

254 **Table 6: Glycyrrhizin contents by RP-HPLC-PDA in Pulmofarm[®] T Premix.**

Sample details	Glycyrrhizin content (ppm)	% Difference in Glycyrrhizin content with respect to control sample
Pulmofarm [®] T Premix - control	2542.91	0.00
Pulmofarm [®] T Premix after exposure to heat for 05 minutes at 90°C	2508.85	-1.36

Pulmofarm [®] T Premix after exposure to heat for 10 minutes at 90°C	2450.54	-3.77
---	---------	-------

255
256
257
258

Table 7: HPTLC analysis data (480 nm) for chloroform fractions of Pulmofarm[®] T Premix samples.


Sample details	Total area of peak of (HPTLC chromatogram at Tungsten 480 nm absorbance)	% Difference in area with respect to control sample
Pulmofarm [®] T Premix - control	0.03517	0.00
Pulmofarm [®] T Premix after exposure to heat for 05 minutes at 90°C	0.03405	-3.29
Pulmofarm [®] T Premix after exposure to heat for 10 minutes at 90°C	0.03309	-6.28

259
260
261

Table 8: HPTLC analysis data (254 nm) of methanol fractions of Pulmofarm[®] T Premix samples.


Sample details	Total area of peak of (HPTLC chromatogram at Deuterium 254 nm absorbance)	% Difference in area with respect to control sample
Pulmofarm [®] T Premix - control	0.02216	0.00
Pulmofarm [®] T Premix after exposure to heat for 05 minutes at 90°C	0.02197	-0.86
Pulmofarm [®] T Premix after exposure to heat for 10 minutes at 90°C	0.02185	-1.42

262



264


265 **Figure 2: HPTLC analysis data (480 nm) of chloroform fractions of Pulmofarm[®] T Premix**
 266 **samples. (A) Chromatograms of control Pulmofarm[®] T Premix sample fraction (zero**
 267 **minute, 90°C temperature, 2.0% w/w moisture content). (B) Chromatograms of treated**
 268 **Pulmofarm[®] T Premix sample fraction (5.0 min, 90°C temperature, 2.0% w/w moisture**
 269 **content). (C) Chromatograms of treated Pulmofarm[®] T Premix sample fraction (10.0 min,**
 270 **90°C temperature, 2.0% w/w moisture content). (D) Three-dimensional overlay**
 271 **chromatogram of (A), (B) and (C).**



273

274 **Figure 3: HPTLC analysis data (254 nm) of methanol fractions of Pulmofarm® T Premix**
 275 **samples. (A) Chromatograms of control Pulmofarm® T Premix sample fraction (zero**
 276 **minute, 90°C temperature, 2.0% w/w moisture content). (B) Chromatograms of treated**
 277 **Pulmofarm® T Premix sample fraction (5.0 min, 90°C temperature, 2.0% w/w moisture**
 278 **content). (C) Chromatograms of treated Pulmofarm® T Premix sample fraction (10.0 min,**
 279 **90°C temperature, 2.0% w/w moisture content). (D) Three-dimensional overlay**
 280 **chromatogram of (A), (B) and (C).**


281



283

284 **Figure 4: RP-HPLC-PDA chromatograms (254 nm) and UV spectrum of glycyrrhizin in**
 285 **control and treated samples of Pulmofarm® T Premix. (A) Standard chromatogram of**
 286 **glycyrrhizin (Rt 16.82). (B) Control sample of Pulmofarm® T Premix (zero minute, 90°C**
 287 **temperature, 2.0% w/w moisture content). (C) Obtained UV-spectral scan for standard and**
 288 **samples. (D) Treated sample of Pulmofarm® T Premix (5.0 minute, 90°C temperature,**
 289 **2.0% w/w moisture content). (E) Treated sample of Pulmofarm® T Premix (10.0 minute,**
 290 **90°C temperature, 2.0% w/w moisture content).**

291



293

294 **Figure 5: RP-HPLC-PDA chromatograms (280 nm) and UV spectrum of thymol in control**
 295 **and treated samples of Pulmofarm® T Premix. (A) Standard chromatogram of thymol (Rt**
 296 **18.47). (B) Control sample of Pulmofarm® T Premix (zero minute, 90°C temperature, 2.0%**
 297 **w/w moisture content). (C) Obtained UV-spectral scan for standard and samples. (D)**
 298 **Treated sample of Pulmofarm® T Premix (5.0 minute, 90°C temperature, 2.0% w/w**
 299 **moisture content). (E) Treated sample of Pulmofarm® T Premix (10.0 minute, 90°C**
 300 **temperature, 2.0% w/w moisture content).**

301

302

303 **4.0 CONCLUSIONS**

304 In conclusion, Pulmofarm[®] T Premix demonstrated stability under pelletization stress conditions,
305 including elevated temperature and increased moisture levels. The results indicate that the
306 formulation can be incorporated as a stable feed supplement during the pelletization process
307 without significant degradation of its key constituents.

308 The present investigation advances to the development of appropriate stability monitoring
309 parameters for herbal formulations. The study provides supporting evidence that
310 chromatographic techniques such as RP-HPLC-PDA and HPTLC, when used in conjunction
311 with established physicochemical evaluations, represent robust analytical approaches for
312 assessing the stability of complex herbal preparations. These techniques can therefore be
313 effectively employed to generate scientifically reliable stability data suitable for regulatory
314 submissions to relevant authorities.

315 Furthermore, the application of these analytical methodologies facilitates the prediction of shelf
316 life and appropriate storage conditions for herbal products. Such assessments are particularly
317 critical for herbal formulations due to their multicomponent composition and inherent chemical
318 complexity, which can influence stability during processing and storage.

319

320

321 **5.0 CONFLICT OF INTEREST**

322 Author has no conflict of interest.

323

324 **6.0 ACKNOWLEDGMENTS**

325 We thank Zenex Animal Health India Private Limited, for providing necessary facilities, help
326 and guidance.

327

328

329 **7.0 REFERENCES**

- 330 1. Wang J, Deng L, Chen M, Che Y, Li L, Zhu L, Chen G, Feng T. Phytogetic feed
331 additives as natural antibiotic alternatives in animal health and production: A review of
332 the literature of the last decade. *Animal Nutrition*. 2024 Jun 1;17:244-64.
- 333 2. Abdallah A, Zhang P, Zhong Q, Sun Z. Application of traditional Chinese herbal
334 medicine by-products as dietary feed supplements and antibiotic replacements in animal
335 production. *Current Drug Metabolism*. 2019 Jan 1;20(1):54-64.
- 336 3. Chmielowiec-Korzeniowska A, Trawińska B, Tymczyna L, Bis-Wencel H, Matuszewski
337 Ł. Microbial contamination of the air in livestock buildings as a threat to human and
338 animal health—a review. *Annals of Animal Science*. 2021 Apr 1;21(2):417-31.
- 339 4. Zhou Y, Shao Z, Dai G, Li X, Xiang Y, Jiang S, Zhang Z, Ren Y, Zhu Z, Fan C, Zhang
340 G. Pathogenic infection characteristics and risk factors for bovine respiratory disease
341 complex based on the detection of lung pathogens in dead cattle in Northeast China.
342 *Journal of Dairy Science*. 2023 Jan 1;106(1):589-606.
- 343 5. Hajare S, Hedau M, Ingawale M, Chauhan S, Ravikanth K, Ganguly B. Acute Oral
344 Toxicity of a Polyherbal Respiratory Tonic. 2020. 08-09.
- 345 6. Roghini R. Ethnobotanical insights into the use of medicinal plants for treating
346 respiratory diseases in the Indian subcontinent. *Afr J Biol Sci*. 2024.
- 347 7. Doba JP, Goti D. Phytopharmacological Evaluation of *Adhatoda Vasica*. *World Journal of*
348 *Pharmaceutical Research*. 2023 Mar 28;12(9):759-80.
- 349 8. Bairwa R, Sodha RS, Rajawat BS. *Trachyspermum ammi*. *Pharmacognosy reviews*. 2012
350 Jan;6(11):56.
- 351 9. Batiha GE, Beshbishy AM, El-Mleeh A, Abdel-Daim MM, Devkota HP. Traditional
352 uses, bioactive chemical constituents, and pharmacological and toxicological activities of
353 *Glycyrrhiza glabra* L. (Fabaceae). *Biomolecules*. 2020 Feb 25;10(3):352.
- 354 10. Cheng H, Sørensen M. Feed manufacturing technology. In *Feed and Feeding for Fish and*
355 *Shellfish 2025* Jan 1 (pp. 279-307). Academic Press.
- 356 11. Paulk CB, Stark CR, Dunmire KM. Feed processing technology and quality of feed.
357 *Sustainable swine nutrition*. 2022 Nov 21:429-44.

- 358 12. Thomas M, Van der Poel AF. Fundamental factors in feed manufacturing: Towards a
359 unifying conditioning/pelleting framework. *Animal feed science and technology*. 2020
360 Oct 1;268:114612.
- 361 13. Kiarie EG, Mills A. Role of feed processing on gut health and function in pigs and
362 poultry: conundrum of optimal particle size and hydrothermal regimens. *Frontiers in*
363 *Veterinary Science*. 2019 Feb 19;6:19.
- 364 14. Thakur L, Ghodasra U, Patel N, Dabhi M. Novel approaches for stability improvement in
365 natural medicines. *Pharmacognosy reviews*. 2011 Jan;5(9):48.
- 366 15. Guideline IH. Validation of analytical procedures Q2 (R2). ICH: Geneva, Switzerland.
367 2022;1.
- 368 16. World Health Organization. (1997). The Medical impact of the use of antimicrobials in
369 food animals: report of a WHO meeting, Berlin, Germany, 13-17 October 1997 (No.
370 WHO/EMC/ZOO/97.4). World Health Organization.
- 371 17. Ravikanth K, Anil K, Deepak T, Anirudh S, Sudheer H. Quality Assurance by Effective
372 Manufacturing Process Validation. *International Journal of Pharmaceutical Quality*
373 *Assurance*. 2015;6(4):109-13.